Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia

Inotuzumab ozogamicin (InO), an anti‐CD22 monoclonal antibody conjugated to calicheamicin, is approved in Europe and the United States for treatment of adults with relapsed or refractory acute lymphoblastic leukemia (ALL). Population analyses were performed to evaluate the relationship between InO e...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Joseph, Haughey, May, Vandendries, Erik, DeAngelo, Daniel J., Kantarjian, Hagop M., Ruiz‐Garcia, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877846/
https://www.ncbi.nlm.nih.gov/pubmed/32812370
http://dx.doi.org/10.1111/cts.12841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877846/
https://www.ncbi.nlm.nih.gov/pubmed/32812370
http://dx.doi.org/10.1111/cts.12841

Ejemplares similares